| 000 | 01780 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250518053113.0 | ||
| 264 | 0 | _c20191017 | |
| 008 | 201910s 0 0 eng d | ||
| 022 | _a1474-547X | ||
| 024 | 7 |
_a10.1016/S0140-6736(19)31282-6 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aEasterling, Thomas | |
| 245 | 0 | 0 |
_aOral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. _h[electronic resource] |
| 260 |
_bLancet (London, England) _cSep 2019 |
||
| 300 |
_a1011-1021 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntihypertensive Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aBlood Pressure _xdrug effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypertension, Pregnancy-Induced _xdrug therapy |
| 650 | 0 | 4 |
_aIndia _xepidemiology |
| 650 | 0 | 4 | _aInfant, Newborn |
| 650 | 0 | 4 |
_aLabetalol _xadministration & dosage |
| 650 | 0 | 4 |
_aMethyldopa _xadministration & dosage |
| 650 | 0 | 4 |
_aNifedipine _xadministration & dosage |
| 650 | 0 | 4 | _aPregnancy |
| 650 | 0 | 4 |
_aPregnancy Outcome _xepidemiology |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aMundle, Shuchita | |
| 700 | 1 | _aBracken, Hillary | |
| 700 | 1 | _aParvekar, Seema | |
| 700 | 1 | _aMool, Sulabha | |
| 700 | 1 | _aMagee, Laura A | |
| 700 | 1 | _avon Dadelszen, Peter | |
| 700 | 1 | _aShochet, Tara | |
| 700 | 1 | _aWinikoff, Beverly | |
| 773 | 0 |
_tLancet (London, England) _gvol. 394 _gno. 10203 _gp. 1011-1021 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S0140-6736(19)31282-6 _zAvailable from publisher's website |
| 999 |
_c29972264 _d29972264 |
||